Cycles of Aberrant Synaptic Sprouting and Neurodegeneration in Alzheimer's and Dementia with Lewy Bodies
The DOI matches its Crossref record; 151 of the 156 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are the most common neurodegenerative disorders affecting the elderly. The cognitive and motor deficits in these diseases are associated with the disruption of neuritic substructure, loss of synaptic contacts in selectively vulnerable circuitries, and aberrant sprouting. Where as in AD, accumulation of misfolded forms of Abeta triggers neurodegeneration, in DLB accumulation of alpha-synuclein might play a central role. The mechanisms by which oligomeric forms of these proteins might lead to cycles of synapse loss and aberrant sprouting are currently under investigation. Several possibilities are being considered, including mitochondrial damage, caspase activation, lysosomal leakage, fragmentation of the Golgi apparatus, interference with synaptic vesicle transport and function, and interference with gene transcription and signaling. Among them, recent lines of research support the possibility that alterations in signaling pathways such extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 relevant to synaptic plasticity and cell survival might play a pivotal role. A wide range of cellular functions are affected by the accumulation of misfolded Abeta and alpha-synuclein; thus it is possible that a more fundamental cellular alteration may underlie the mechanisms of synaptic pathology in these disorders. Among them, one possibility is that scaffold proteins, such as caveolin and JNK-interac…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“7), recent studies have shown that missense mutations (Ala53 to Thr, Ala30 to Pro) in -synuclein are associated with familial parkinsonism (125,126) and that mutant (mut) -synuclein is more prone to aggregate (127–129) and is the principal component of the LBs (120,122).”
BackgroundGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118 · cited 1×
“Furthermore, expression of human -synuclein in some transgenic (tg) mouse lines (130) and fly recapitulates several aspects of PD, such as formation of inclusion bodies and dysfunction of dopaminergic neurons (131).”
BackgroundNeurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“Supporting this view, several lines of investigation have shown that APP and its proteolytic fragments play a role in guiding growing neurites in the fetal brain (93,94), and in vitro studies have suggested that, depending on the concentration, APP and its fragments could be neurotoxic or neurotrophic (95).”
BackgroundMucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“This sequence of events is consistent with experimental studies in the aged macaque (37) and in transgenic models of AD, in which synaptic loss and memory deficits precede amyloid deposition and plaque formation, but are associated with increased production of A 1–42 in the limbic system (31,38).”
ResultSelf-citationMasliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 1×
“Furthermore, expression of human -synuclein in some transgenic (tg) mouse lines (130) and fly recapitulates several aspects of PD, such as formation of inclusion bodies and dysfunction of dopaminergic neurons (131).”
BackgroundSelf-citationMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Furthermore, APP is transported by fast axonal transport to the nerve terminals, where it might play a role in modulating memory formation (96,97) and glutamate levels at the synaptic cleft (98).”
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605 · cited 1×
“Several possibilities have been postulated; among them, some studies suggest that increased lysosomal leakage, increased intracellular trafficking of calcium, accumulation of intracellular A in the synapse (114), reduced synaptic vesicle trafficking (115,116), deficient axonal transport, abnormal activation of signali…”
BackgroundConway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Okamoto, T., Schlegel, A., Scherer, P. E., & Lisanti, M. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5419 · Cited by 1,498 · cited 1×
“Caveolin-1 is the member of the caveolin family of peptides (caveolin-1, -2 and -3), which have scaffold functions and are involved in the assembly and regulation of caveolar signaling molecules (156).”
BackgroundMolecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11282 · Cited by 1,480 · cited 1×
“-Synuclein is a 140-amino-acid (aa) presynaptic protein, that was previously identified as the precursor of the non– amyloid component of AD amyloid plaque (124) (Fig.”
BackgroundSelf-citationIncreased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,465
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316 · cited 1×
“Further supporting a role for synaptic pathology in DLB, previous studies have shown that Lewy bodies (LB) display synaptophysin immunoreactivity (61) and, more importantly, -synuclein, the main component of the inclusions (62–64) in DLB, is an abundant presynaptic terminal protein (65).”
Self-citationPathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn983 · Cited by 1,283
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Caveolins, Liquid-Ordered Domains, and Signal Transduction
Smart, E. J., Graf, G. A., McNiven, M. A., Sessa, W. C., Engelman, J. A., Scherer, P. E., Okamoto, T., & Lisanti, M. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7289 · Cited by 1,006 · cited 2×
“Since it has been recently shown that caveolar function and the ERK signaling pathway are integrated in regulating synaptic plasticity (154,155), we hypothesized that -synuclein–mediated alterations in caveolar function might also result in dysregulation of the ERK signaling pathway.”
BackgroundCabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865 · cited 1×
“Several possibilities are being considered, including mitochondrial damage (134), lysosomal leakage (141), fragmentation of the Golgi apparatus (142), interference with synaptic vesicle transport and function (143), and interference with gene transcription and signaling (144) (Fig.”
BackgroundLee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824 · cited 1×
“In other tg mouse lines, overexpression of mut -synuclein results in neuronal accumulation of -synuclein and severe motor alterations (132,133).”
BackgroundBraak, F., Braak, H., & Mandelkow, E. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 772
Xu, J., Kao, S.-Y., Lee, F. J. S., Song, W., Jin, L.-W., & Yankner, B. A. (2002) · Nature Medicine · doi:10.1038/nm0602-600 · Cited by 757 · cited 2×
“Furthermore, it has been shown that -synuclein may interact with 14-3-3, the regulator of multiple signaling molecules, suggesting that -synuclein might affect various signaling pathways indirectly through 14-3-3 (138,145).”
BackgroundAltered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720 · cited 1×
“The wide range of cellular functions affected by the accumulation of misfolded -synuclein and A suggests that a more fundamental cellular alteration may underlie the mechanisms of synaptic pathology in these disorders (32).”
BackgroundSelf-citationα-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress
Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., & Masliah, E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64553-1 · Cited by 714
Self-citationTakahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706 · cited 1×
“Several possibilities have been postulated; among them, some studies suggest that increased lysosomal leakage, increased intracellular trafficking of calcium, accumulation of intracellular A in the synapse (114), reduced synaptic vesicle trafficking (115,116), deficient axonal transport, abnormal activation of signali…”
BackgroundAmyloid diseases: Abnormal protein aggregation in neurodegeneration
Koo, E. H., Lansbury, P. T., & Kelly, J. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9989 · Cited by 693 · cited 1×
“APP, a molecule suggested to be centrally involved in AD (82,83), has been demonstrated to be transported in the axon to the presynaptic site (84), where it might play a role in synaptic plasticity.”
BackgroundKirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649
ULTRASTRUCTURAL STUDIES IN ALZHEIMER'S PRESENILE DEMENTIA.
Terry, R. D., Gonatas, N. K., & WEISS, M. (1964) · PubMed Central · Cited by 644
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Davies, C. A., Mann, D. M. A., Sumpter, P. Q., & Yates, P. O. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90057-8 · Cited by 628
Impey, S., Obrietan, K., & Storm, D. R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80747-3 · Cited by 613
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607
Self-citationAlpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M. Y., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1916 · Cited by 601
Membrane microdomains and caveolae
Kurzchalia, T. V., & Partan, R. G. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80061-1 · Cited by 579
β-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease
Fukumoto, H. (2002) · Archives of Neurology · doi:10.1001/archneur.59.9.1381 · Cited by 575
α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins
Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., & Wolozin, B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-14-05782.1999 · Cited by 564
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
Lansbury, P. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3342 · Cited by 553
A Portrait of Alzheimer Secretases--New Features and Familiar Faces
Esler, W. P., & Wolfe, M. S. (2001) · Science · doi:10.1126/science.1064638 · Cited by 493 · cited 1×
“C99 is further cleaved by ( -secretase), resulting in the production of A peptides, which vary in length (106) (Fig.”
BackgroundSynaptic loss in Alzheimer's disease and other dementias
Hamos, J. E., DeGennaro, L. J., & Drachman, D. A. (1989) · Neurology · doi:10.1212/wnl.39.3.355 · Cited by 432
Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques.
Dickson, D. W., Farlo, J., Davies, P., Crystal, H., Fuld, P. A., & Yen, S. H. (1988) · PubMed · Cited by 427
Correlations of synaptic and pathological markers with cognition of the elderly
Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., & Davies, P. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00013-5 · Cited by 410 · cited 2×
“For example, the levels of the synaptic-like marker EP10 in all cortical areas and the hippocampus were correlated (p .05–0.01) with the Blessed test, but not with the Object Memory Examination (48).”
MethodInfluentialClinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias
Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W., Masliah, E., Terry, R., Hill, L. R., Lessin, P., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 409
Self-citationAbnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
Takeda, A., Mallory, M. E., Sundsmo, M. P., Honer, W. G., Hansen, L. A., & Masliah, E. (1998) · Europe PMC (PubMed Central) · Cited by 403
Self-citationPalop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G.-Q., Raber, J., Masliah, E., & Mucke, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133381100 · Cited by 402
Self-citationKosaka, K., Yoshimura, M., Ikeda, K., & Budka, H. (1984) · PubMed · Cited by 401
Matthews, D. A., Cotman, C., & Lynch, G. (1976) · Brain Research · doi:10.1016/0006-8993(76)90820-9 · Cited by 384
Gearing, M., Mirra, S. S., Hedreen, J. C., Sumi, S. M., Hansen, L. A., & Heyman, A. (1995) · Neurology · doi:10.1212/wnl.45.3.461 · Cited by 380
Masliah, E., Sisk, A., Mallory, M., Mucke, L., Schenk, D., & Games, D. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-18-05795.1996 · Cited by 370
Self-citationSynaptic and neuritic alterations during the progression of Alzheimer's disease
Masliah, E., Mallory, M., Hansen, L., Richard, D., Alford, M., & Terry, R. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90121-x · Cited by 370
Self-citationImmunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease
Masliah, E., Terry, R. D., DeTeresa, R. M., & Hansen, L. A. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90582-x · Cited by 363
Self-citationA quantitative electron microscopic study of synaptogenesis in the dentate gyrus of the rat
Crain, B., Cotman, C., Taylor, D., & Lynch, G. (1973) · Brain Research · doi:10.1016/0006-8993(73)90088-7 · Cited by 349
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., & Takahashi, H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00891-4 · Cited by 331
Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.
Masliah, E., Terry, R. D., Alford, M. F., DeTeresa, R. M., & Hansen, L. A. (1991) · PubMed · Cited by 328
Self-citationTrojanowski, J. Q., Goedert, M., Iwatsubo, T., & Lee, V. M.-Y. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400432 · Cited by 297 · cited 3×
“DLB is characterized by behavioral and motor deficits associated with synapse and neuronal loss in the striatonigral system, limbic system, and neocortex and formation of -synuclein containing LBs and plaque formation (25–27,119).”
BackgroundGosavi, N., Lee, H.-J., Lee, J. S., Patel, S., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208194200 · Cited by 294 · cited 1×
“Several possibilities are being considered, including mitochondrial damage (134), lysosomal leakage (141), fragmentation of the Golgi apparatus (142), interference with synaptic vesicle transport and function (143), and interference with gene transcription and signaling (144) (Fig.”
BackgroundHashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A., Sundsmo, M., & Masliah, E. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00514-9 · Cited by 267
Self-citationLocalization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites
Schubert, W., Prior, R., Weidemann, A., Dircksen, H., Multhaup, G., Masters, C. L., & Beyreuther, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91532-6 · Cited by 265
Synapse loss in the temporal lobe in Alzheimer's disease
Scheff, S. W., & Price, D. A. (1993) · Annals of Neurology · doi:10.1002/ana.410330209 · Cited by 263 · cited 3×
“There were no correlations between synaptic density and synaptic apposition length or density of senile plaques (51).”
BackgroundEl-Agnaf, O. M. A., Jakes, R., Curran, M. D., & Wallace, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01419-7 · Cited by 258
Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease
Hashimoto, M., & Masliah, E. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00552.x · Cited by 254 · cited 3×
“DLB is characterized by behavioral and motor deficits associated with synapse and neuronal loss in the striatonigral system, limbic system, and neocortex and formation of -synuclein containing LBs and plaque formation (25–27,119).”
BackgroundSelf-citationPatterns of aberrant sprouting in alzheimer's disease
Masliah, E., Mallory, M., Hansen, L., Alford, M., Albright, T., DeTeresa, R., Terry, R., Baudier, J., & Saitoh, T. (1991) · Neuron · doi:10.1016/0896-6273(91)90170-5 · Cited by 244 · cited 6×
“Recent studies in the aged monkey (79,80), as well as in the AD and DLB cortex (44,81), have shown that the abnormal neuritic elements in the plaque contain several synaptic and axonal specific proteins, including amyloid precursor protein (APP), GAP-43, chromogranin, synaptophysin, EP10 antigen, SV-2, p65, synapsin,…”
BackgroundSelf-citationFall, P.-A., Fredrikson, M., Axelson, O., & Gran�rus, A.-K. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1<28::aid-mds1007>3.0.co;2-o · Cited by 244
Research advances in Alzheimer's disease and related disorders
Iqbal, K., & Disorders, R. (1995) · Wiley eBooks · Cited by 228
Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., & Lau, Y.-S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03514-x · Cited by 212 · cited 1×
“Several possibilities are being considered, including mitochondrial damage (134), lysosomal leakage (141), fragmentation of the Golgi apparatus (142), interference with synaptic vesicle transport and function (143), and interference with gene transcription and signaling (144) (Fig.”
BackgroundYao, P. J., Zhu, M., Pyun, E. I., Brooks, A. I., Therianos, S., Meyers, V. E., & Coleman, P. D. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(02)00009-8 · Cited by 206 · cited 1×
“Several possibilities have been postulated; among them, some studies suggest that increased lysosomal leakage, increased intracellular trafficking of calcium, accumulation of intracellular A in the synapse (114), reduced synaptic vesicle trafficking (115,116), deficient axonal transport, abnormal activation of signali…”
BackgroundBlennow, K., Bogdanovic, N., Alafuzoff, I., Ekman, R., & Davidsson, P. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273157 · Cited by 206
The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Proteina
SELKOE, D. J., YAMAZAKI, T., CITRON, M., PODLISNY, M. B., KOO, E. H., TEPLOW, D. B., & HAASS, C. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34401.x · Cited by 205
Hashimoto, M., Hsu, L. J., Rockenstein, E., Takenouchi, T., Mallory, M., & Masliah, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111428200 · Cited by 205 · cited 6×
“Several possibilities are being considered, including mitochondrial damage (134), lysosomal leakage (141), fragmentation of the Golgi apparatus (142), interference with synaptic vesicle transport and function (143), and interference with gene transcription and signaling (144) (Fig.”
BackgroundSelf-citationDiffuse Lewy body disease: Neuropathological and biochemical studies of six patients
Dickson, D. W., Davies, P., Mayeux, R., Crystal, H., Horoupian, D. S., Thompson, A., & Goldman, J. E. (1987) · Acta Neuropathologica · doi:10.1007/bf00686786 · Cited by 205 · cited 1×
“This condition has also been called Lewy body variant of AD (22), dementia of the Lewy body type, and diffuse Lewy body disease (23,24).”
BackgroundMasliah, E., Fagan, A. M., Terry, R. D., DeTeresa, R., Mallory, M., & Gage, F. H. (1991) · Experimental Neurology · doi:10.1016/0014-4886(91)90169-d · Cited by 204 · cited 2×
“While searching for an experimental model to test and validate a newly developed assay to visualize synaptic alterations in the nervous system in a fast and reliable manner, we came across this extraordinary series of papers following discussions with Robert Terry and Rusty Gage (10).”
BackgroundMethodSelf-citationSpine Loss and Regrowth in Hippocampus following Deafferentation
PARNAVELAS, J. G., LYNCH, G., BRECHA, N., COTMAN, C. W., & GLOBUS, A. (1974) · Nature · doi:10.1038/248071a0 · Cited by 198
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
Tabrizi, S. J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2683 · Cited by 197
Cotman, C. W., Matthews, D. A., Taylor, D., & Lynch, G. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.12.3473 · Cited by 191
Gonatas, N. K., Anderson, W., & Evangelista, I. (1967) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196701000-00003 · Cited by 186 · cited 1×
“In addition, ultrastructural studies have shown that in AD the synapses are swollen and contain abnormal accumulation of cytoskeletal proteins, vesicles, and lysosomes (67,70, 71).”
BackgroundKoo, E. H., Park, L., & Selkoe, D. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4748 · Cited by 181 · cited 1×
“APP, a molecule suggested to be centrally involved in AD (82,83), has been demonstrated to be transported in the axon to the presynaptic site (84), where it might play a role in synaptic plasticity.”
BackgroundLewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177
Huse, J. T., Liu, K., Pijak, D. S., Carlin, D., Lee, V. M.-Y., & Doms, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111141200 · Cited by 176
Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease
Masliah, E., Hansen, L., Albright, T., Mallory, M., & Terry, R. D. (1991) · Acta Neuropathologica · doi:10.1007/bf00293464 · Cited by 174 · cited 1×
“In addition, ultrastructural studies have shown that in AD the synapses are swollen and contain abnormal accumulation of cytoskeletal proteins, vesicles, and lysosomes (67,70, 71).”
BackgroundSelf-citation(1994) · PubMed Central · Cited by 169
(2000) · doi:10.1016/s0306-4522(00)00077-4 · Cited by 167
Grace, E. A., Rabiner, C. A., & Busciglio, J. A. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00241-5 · Cited by 166 · cited 1×
“In contrast, aggregated A interacts with the integrin, leading to signaling though the focal adhesion pathway (100).”
BackgroundSenile plaques as aberrant sprout-stimulating structures
Geddes, J. W., Anderson, K. J., & Cotman, C. W. (1986) · Experimental Neurology · doi:10.1016/0014-4886(86)90254-2 · Cited by 161 · cited 1×
“Whereas some groups postulate that they represent degenerating processes, others suggest that at least a subpopulation of them might be aberrant sprouting neurites (13,76,77), based on the presence of the growth associated protein43 (GAP-43) (76,78) (Fig.”
BackgroundLassmann, H., Weiler, R., Fischer, P., Bancher, C., Jellinger, K., Floor, E., Danielczyk, W., Seitelberger, F., & Winkler, H. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90003-k · Cited by 160
Oxidative Stress, Perturbed Calcium Homeostasis, and Immune Dysfunction in Alzheimer's Disease
Mattson, M. P. (2002) · Journal of NeuroVirology · doi:10.1080/13550280290100978 · Cited by 157
Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimerʼs Disease
Samuel, W., Galasko, D., Masliah, E., & Hansen, L. A. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199601000-00005 · Cited by 145 · cited 1×
“Whereas midfrontal cortex synapse density was the strongest correlate of AD dementia severity, followed by NFTs, in DLB there was only a weak correlation between midfrontal synapse loss and Blessed score (59).”
BackgroundSelf-citationα-Synuclein Affects the MAPK Pathway and Accelerates Cell Death
Iwata, A., Maruyama, M., Kanazawa, I., & Nukina, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103736200 · Cited by 139 · cited 1×
“The mechanisms by which -synuclein suppresses ERK signaling pathway are unknown, however it is possible that misfolded -synuclein might directly interact with ERK through the chaperone-like functions of -synuclein (145,146) or by binding to other ERK-related signaling molecules, such as Elk-1 (152) (Fig.”
BackgroundAhn, B.-H., Rhim, H., Kim, S. Y., Sung, Y.-M., Lee, M.-Y., Choi, J.-Y., Wolozin, B., Chang, J.-S., Lee, Y. H., Kwon, T. K., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110414200 · Cited by 136
Fibroblast Growth Factor 1 Regulates Signaling via the Glycogen Synthase Kinase-3β Pathway
Hashimoto, M., Sagara, Y., Langford, D., Everall, I. P., Mallory, M., Everson, A., Digicaylioglu, M., & Masliah, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202803200 · Cited by 127 · cited 1×
“growth, are also activated in response to damage/oxidative stress (140).”
BackgroundSelf-citationAn introduction to molecular neurobiology
(1992) · Choice Reviews Online · doi:10.5860/choice.30-1496 · Cited by 125
Cummings, B. J., Su, J. H., Geddes, J. W., Van Nostrand, W. E., Wagner, S. L., Cunningham, D. D., & Cotman, C. W. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90265-4 · Cited by 120 · cited 1×
“Whereas some groups postulate that they represent degenerating processes, others suggest that at least a subpopulation of them might be aberrant sprouting neurites (13,76,77), based on the presence of the growth associated protein43 (GAP-43) (76,78) (Fig.”
BackgroundDevelopment of senile plaques. Relationships of neuronal abnormalities and amyloid deposits.
Cork, L. C., Masters, C. L., Beyreuther, K. T., & Price, D. L. (1990) · Europe PMC (PubMed Central) · Cited by 116
Zhan, S.-S., Beyreuther, K., & Schmitt, H. P. (1993) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107299 · Cited by 110 · cited 1×
“These findings have been confirmed by immunochemical quantification of various synaptic proteins (46,47).”
BackgroundSamuel, W., Masliah, E., Hill, L. R., Butters, N., & Terry, R. (1994) · Neurology · doi:10.1212/wnl.44.11.2081 · Cited by 108 · cited 1×
“Cases displaying clinical and neuropathological features of early or incipient AD showed a significant 20% loss of synapses in the outer molecular layer of the hippocampal dentate gyrus (41,42).”
BackgroundSelf-citationCotman, C. W., & Anderson, K. J. (1988) · PubMed · Cited by 106
Roßner, S., Apelt, J., Schliebs, R., Perez‐Polo, J. R., & Bigl, V. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1095 · Cited by 103
Wakabayashi, K., Honer, W. G., & Masliah, E. (1994) · Brain Research · doi:10.1016/0006-8993(94)91709-4 · Cited by 102 · cited 2×
“Cases displaying clinical and neuropathological features of early or incipient AD showed a significant 20% loss of synapses in the outer molecular layer of the hippocampal dentate gyrus (41,42).”
BackgroundSelf-citationMasliah, E., Mallory, M. E., Hansen, L. A., Alford, M. F., DeTeresa, R. M., Terry, R. D., Baudier, J., & Saitoh, T. (1992) · Brain Research · doi:10.1016/0006-8993(92)90831-s · Cited by 96 · cited 2×
“Three-dimensional reconstruction of the plaques revealed that anti-APP was colocalized with anti-GAP43 in 57% of the aberrant sprouting neurites (86).”
BackgroundSelf-citationalpha-Synuclein forms a complex with transcription factor Elk-1
Iwata, A., Miura, S., Kanazawa, I., Sawada, M., & Nukina, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00232.x · Cited by 95
Weiler, R., Lassmann, H., Fischer, P., Jellinger, K., & Winkler, H. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81408-g · Cited by 89 · cited 1×
“These findings have been confirmed by immunochemical quantification of various synaptic proteins (46,47).”
BackgroundAmyloid precursor protein is localized in growing neurites of neonatal rat brain
Masliah, E., Mallory, M. E., Ge, N., & Saitoh, T. (1992) · Brain Research · doi:10.1016/0006-8993(92)91329-d · Cited by 84 · cited 1×
“Supporting this view, several lines of investigation have shown that APP and its proteolytic fragments play a role in guiding growing neurites in the fetal brain (93,94), and in vitro studies have suggested that, depending on the concentration, APP and its fragments could be neurotoxic or neurotrophic (95).”
BackgroundSelf-citationHashimoto, M., Takenouchi, T., Rockenstein, E., & Masliah, E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01791.x · Cited by 83 · cited 1×
“Consistent with this, -synuclein overexpressing cells exhibited significantly lower activity of ERK compared to both the control and -synuclein overexpressing cells, providing an ideal system for the investigation of the mechanism of the suppression of ERK by -synuclein (153).”
BackgroundSelf-citationQuantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease
Scheff, S. W., Sparks, D. L., & Price, D. A. (1993) · Annals of Neurology · doi:10.1002/ana.410340309 · Cited by 82 · cited 1×
“In contrast, in the EC no change in synaptic density between control and AD, in either lamina III or V, was observed (53).”
BackgroundReduced Neuritic Outgrowth and Cell Adhesion in Neuronal Cells Transfected with Human α-Synuclein
Takenouchi, T., Hashimoto, M., Hsu, L. J., Mackowski, B., Rockenstein, E. M., Mallory, M. E., & Masliah, E. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0923 · Cited by 78 · cited 3×
“In the B103 cell line, -synuclein overexpression results in the formation of discrete aggregates in the cell body and processes and reduced neurite outgrowth (139), mimicking another important aspect of DLB, namely compromised axonal plasticity (89).”
BackgroundSelf-citationAlzheimer's and Parkinson's disease – overlapping or synergistic pathologies?
Kurosinski, P., Guggisberg, M., & Götz, J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02246-8 · Cited by 75 · cited 2×
“DLB is an heterogeneous group of disorders that combine AD and PD (20,21).”
BackgroundSynaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains
Nishimura, M., Tomimoto, H., Suenaga, T., Nakamura, S., Namba, Y., Ikeda, K., Akiguchi, I., & Kimura, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91940-2 · Cited by 73 · cited 1×
“Further supporting a role for synaptic pathology in DLB, previous studies have shown that Lewy bodies (LB) display synaptophysin immunoreactivity (61) and, more importantly, -synuclein, the main component of the inclusions (62–64) in DLB, is an abundant presynaptic terminal protein (65).”
BackgroundFrontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia
Hansen, L. A., Daniel, S. E., Wilcock, G. K., & Love, S. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.5.653 · Cited by 73
Alpha-synuclein and Parkinson's disease
Golbe, L. I. (1999) · Movement Disorders · doi:10.1002/1531-8257(199901)14:1<6::aid-mds1004>3.0.co;2-l · Cited by 70
A Novel SNAP25–Caveolin Complex Correlates with the Onset of Persistent Synaptic Potentiation
Braun, J. E. A., & Madison, D. V. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-05997.2000 · Cited by 69 · cited 2×
“Since it has been recently shown that caveolar function and the ERK signaling pathway are integrated in regulating synaptic plasticity (154,155), we hypothesized that -synuclein–mediated alterations in caveolar function might also result in dysregulation of the ERK signaling pathway.”
BackgroundAlzheimer's disease-related synapse loss in the cingulate cortex
Scheff, S. W., & Price, D. A. (2001) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2001-3509 · Cited by 66 · cited 1×
“Ultrastructural analyses have shown a highly significant AD-related decline in synaptic numbers in lamina III and V in both superior and middle temporal gyrus (51) and cingulate cortex (52).”
BackgroundSynaptic Proteins in Alzheimer's Disease
Marksteiner, J., Kaufman, W. A., Gurka, P., & Humpel, C. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:53 · Cited by 66
APP is required during an early phase of memory formation
Mileusnic, R., Lancashire, C. L., Johnston, A. N. B., & Rose, S. P. R. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.01344.x · Cited by 66 · cited 1×
“Furthermore, APP is transported by fast axonal transport to the nerve terminals, where it might play a role in modulating memory formation (96,97) and glutamate levels at the synaptic cleft (98).”
BackgroundMasliah, E., Mallory, M. E., DeTeresa, R. M., Alford, M. F., & Hansen, L. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)91093-8 · Cited by 63
Self-citationThe Lewy body variant of Alzheimer disease
Hansen, L. A. (1997) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6846-2_7 · Cited by 62 · cited 1×
“This condition has also been called Lewy body variant of AD (22), dementia of the Lewy body type, and diffuse Lewy body disease (23,24).”
BackgroundCox, M. E., & Parsons, S. J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031119.x · Cited by 62 · cited 1×
“More specifically, ERK has been implicated in the regulation of dopamine and catecholamine secretions (149,150) and studies of -synuclein knockout mice suggested that -synuclein may negatively regulate dopamine release at synaptic terminals (151), thus indicating that suppression of ERK by -synuclein might lead to dec…”
BackgroundMasliah, E., Honer, W. G., Mallory, M. E., Voigt, M., Kushner, P. D., Hansen, L. A., & Terry, R. D. (1994) · Acta Neuropathologica · doi:10.1007/bf00296182 · Cited by 60 · cited 1×
“(44,81), have shown that the abnormal neuritic elements in the plaque contain several synaptic and axonal specific proteins, including amyloid precursor protein (APP), GAP-43, chromogranin, synaptophysin, EP10 antigen, SV-2, p65, synapsin, tau, and phosphorylated neurofilaments (detected by monoclonal antibody SMI 312…”
BackgroundSelf-citationJones, D. G., & Harris, R. J. (1995) · Reviews in the Neurosciences · doi:10.1515/revneuro.1995.6.3.177 · Cited by 60 · cited 2×
“For a comprehensive review of the subject the reader is advised to consult Jones and Harris (72).”
BackgroundAβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD
Masliah, E., Alford, M., Adame, A., Rockenstein, E., Galasko, D., Salmon, D., Hansen, L. A., & Thal, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000073987.79060.4b · Cited by 53 · cited 1×
“More recent studies have shown that of the products of the -secretory pathway, soluble A 42 stimulates sprouting of cholinergic fibers (99).”
BackgroundSelf-citationAmyloid Protein Precursor Stimulates Excitatory Amino Acid Transport
Masliah, E., Raber, J., Alford, M., Mallory, M., Mattson, M. P., Yang, D., Wong, D., & Mucke, L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12548 · Cited by 52 · cited 1×
“Furthermore, APP is transported by fast axonal transport to the nerve terminals, where it might play a role in modulating memory formation (96,97) and glutamate levels at the synaptic cleft (98).”
BackgroundSelf-citationChan, S. L., Furukawa, K., & Mattson, M. P. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:167 · Cited by 52 · cited 1×
“Several possibilities have been postulated; among them, some studies suggest that increased lysosomal leakage, increased intracellular trafficking of calcium, accumulation of intracellular A in the synapse (114), reduced synaptic vesicle trafficking (115,116), deficient axonal transport, abnormal activation of signali…”
BackgroundMechanisms of synaptic pathology in Alzheimer’s disease
Masliah, E. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_13 · Cited by 51 · cited 1×
“Cases presenting with more severe disease showed a progressively more significant loss of synapses in the neocortex, as well as in the outer molecular layer of the hippocampal dentate gyrus (43).”
BackgroundSelf-citationCotman, C. W., Gentry, C. A., & Steward, O. (1977) · Journal of Neurocytology · doi:10.1007/bf01178228 · Cited by 48
Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease
Arai, H., Schmidt, M. L., Lee, V. M.-Y., Hurtig, H. I., Greenberg, B. D., Adler, C. H., & Trojanowski, J. Q. (1992) · Neurology · doi:10.1212/wnl.42.7.1315 · Cited by 46 · cited 1×
“(44,81), have shown that the abnormal neuritic elements in the plaque contain several synaptic and axonal specific proteins, including amyloid precursor protein (APP), GAP-43, chromogranin, synaptophysin, EP10 antigen, SV-2, p65, synapsin, tau, and phosphorylated neurofilaments (detected by monoclonal antibody SMI 312…”
BackgroundAbnormal brain spectrin immunoreactivity in sprouting neurons in Alzheimer disease
Masliah, E., Hansen, L. A., Mallory, M. E., Albright, T., & Terry, R. D. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90707-z · Cited by 34 · cited 1×
“In fact, the severity of this process in DLB is more extensive than in DLB (88,89).”
BackgroundSelf-citationThe Role of Misdirected Plasticity in Plaque Biogenesis and Alzheimer’s Disease Pathology
Cotman, C. W., Cummings, B. J., & Whitson, J. S. (1991) · Springer eBooks · doi:10.1007/978-3-642-46722-6_19 · Cited by 31
beta-Amyloid, protein processing and Alzheimer's disease.
Haas, C., Hung, A. Y., Citron, M., Teplow, D. B., & Selkoe, D. J. (1995) · PubMed · Cited by 31
Bloch‐Shilderman, E., Jiang, H., Abu‐Raya, S., Michal Linial, B., & Lazarovici, P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38806-8 · Cited by 27 · cited 1×
“More specifically, ERK has been implicated in the regulation of dopamine and catecholamine secretions (149,150) and studies of -synuclein knockout mice suggested that -synuclein may negatively regulate dopamine release at synaptic terminals (151), thus indicating that suppression of ERK by -synuclein might lead to dec…”
BackgroundAbnormal synaptic regeneration in hAPP transgenic and ApoE knockout mice
San Diego, C. A. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)92498-8 · Cited by 26
H�ggendal, J. (1982) · Journal of Neural Transmission · doi:10.1007/bf01243406 · Cited by 18
Alzheimer's disease is a degenerative disorder.
Katzman, R. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90137-1 · Cited by 18
Younkin, S. G. (1998) · Springer eBooks · doi:10.1007/978-3-642-72103-8_4 · Cited by 17
Chapter 15. Neurodegenerative Dementias
LoBue, C., Cullum, C. M., Didehbani, N., Yeatman, K., Jones, B. H., Kraut, M. A., & Hart, J. A. L. (2018) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372645.js15 · Cited by 15
The Pathology of the Synapse in Alzheimer's Disease
Gonatas, N. K., & Gambetti, P. L. (1970) · Novartis Foundation symposium · doi:10.1002/9780470719749.ch11 · Cited by 14
Deafferentative Synaptopathology in Physiological Aging and Alzheimer's Disease
Bertoni–Freddari, C., Fattoretti, P., DELFINO, A., Solazzi, M., Giorgetti, B., ULRICH, J., & Meier-Ruge, W. A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04833.x · Cited by 13 · cited 1×
“The concomitant atrophy and loss of dendritic spines in AD also contributes to severity of the dementia (49,50).”
BackgroundRecent Advances in the Understanding of the Processing of APP to Beta Amyloid Peptide
SINHA, S., ANDERSON, J., JOHN, V., McCONLOGUE, L., BASI, G., THORSETT, E., & SCHENK, D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06923.x · Cited by 12
Natural evolution of the neurodegenerative alterations in Alzheimer's disease
Masliah, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00020-f · Cited by 11 · cited 1×
“This sequence of events is consistent with experimental studies in the aged macaque (37) and in transgenic models of AD, in which synaptic loss and memory deficits precede amyloid deposition and plaque formation, but are associated with increased production of A 1–42 in the limbic system (31,38).”
ResultSelf-citationSix, J., bke, U. L. ⁄., Lenders, M., Vandermeeren, M., Mercken, M. H., Villanova, M., Vandevoorde, A., Gheuens, J., Martin, J.-J., & Cras, P. P. (1992) · Neurodegeneration · Cited by 9
Neuropathological Correlates of Dementia in Alzheimer’s Disease
Masliah, E., & Salmon, D. P. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_15 · Cited by 8 · cited 1×
“The damage to these circuitries in early stages of AD results in memory loss followed by attention deficits, judgment impairments, mood changes, confusion, and inability to maintain purposeful thinking (40) (Fig.”
BackgroundSelf-citationRELATIONSHIPS OF ABNORMAL NEURONAL PROCESSES AND AMYLOID IN PLAQUES IN AGED MONKEYS
Cork, L. C., & Price, D. L. (1990) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199005000-00152 · Cited by 4 · cited 1×
“Recent studies in the aged monkey (79,80), as well as in the AD and DLB cortex”
Background
Research works printed but not linked: 9
- Eccles, J. 1984. The cerebral neocortex: A theory of its operation. Pages 1-38, in Jones, E. and Peters, A. (eds.), Cerebral Cortex, Vol. 2, Functional Properties of Cortical Cells, New York, Plenum.
- Cotman, C. and Nadler, J. 1978. Reactive synaptogenesis in the hippocampus. Pages 227-271, in Cotman, C. (ed.), Neuronal Plasticity, New York, Raven.
- Cotman, C., Cummings, B., and Pike, C. 1993. Molecular cascades in adaptive versus pathological plasticity. Pages 217-240, in Gorio, A. (ed.), Neurodegeneration, New York, Raven.
- Terry, R., Hansen, L., and Masliah, E. 1994. Structural basis of the cognitive alterations in Alzheimer disease. Pages 179-196, in Terry, R. and Katzman, R. (eds.), Alzheimer Disease, New York, Raven.
- Masliah, E. and LiCastro, F. 2000. Neuronal and synaptic loss, reactive gliosis, microglial response, and induction of the complement cascade in Alzheimer's disease. Pages 131-146, in Clark, C. and Trojanowski, J. Neurodegenerative Dementias, New York, McGraw-Hill.
- Hof, P. and Morrison, J. 1994. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. Pages 197-230, in Terry, R., Katzman, R., and Bick, K. (eds.), Alzheimer Disease, New York, Raven.
- Anderson, B. 1995. Dendritic correlates of dementia severity in Alzheimer's disease. Med. Sci. Res. 23:597-599.
- Masliah, E. and Terry, R. 1994. The role of synaptic pathology in the mechanisms of dementia in Alzheimer's disease. Clin. Neurosci. 1:192-198.
- Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., and Mucke, L. 2001. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA 98:12245-12250. · DOI · Paper page
Cited by
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Garcia‐Alloza, M., Borrelli, L. A., Rozkalne, A., Hyman, B. T., & Bacskai, B. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04613.x · Cited by 661
Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., & Masliah, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4390-09.2009 · Cited by 595
“This model was selected because overexpression of -syn in these cells results in mitochondrial alterations, reduced cell viability, defective neurite outgrowth, and abnormal accumulation of oligomeric -syn (Takenouchi et al., 2001; Hashimoto and Masliah, 2003).”
BackgroundSelf-citationFunctional Alterations in Memory Networks in Early Alzheimer’s Disease
Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 604
“Alternatively, increased regional brain activation may be a marker of the pathophysiologic process of AD itself, such as aberrant sprouting of cholinergic fibers (Hashimoto and Masliah 2003) or inefficiency in synaptic transmission (Stern et al. 2004).”
BackgroundMedial temporal lobe function and structure in mild cognitive impairment
Dickerson, B. C., Salat, D. H., Bates, J. F., Atiya, M., Killiany, R. J., Greve, D. N., Dale, A. M., Stern, C. E., Blacker, D., Albert, M. S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20163 · Cited by 566
Metadata
- Authors
- Hashimoto, M., & Masliah, E.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Masliah, Eliezer
- Venue
- Neurochemical Research
- Published
- 2003-11
- Volume
- 28
- Issue
- 11
- Pages
- 1743-1756
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W321625949
- Cited by
- 78
- References
- 156
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 2
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Neurochemical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ag010869-05)
- National Institute on Aging (P50AG005131, AG-5131, AG 18440, AG10869)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, dementia with Lewy bodies, synaptic loss, neurodegeneration, amyloid-beta, alpha-synuclein, protein oligomers, ERK signaling, JNK signaling, p38 MAPK, caveolin, synaptic plasticity, mitochondrial damage, Golgi fragmentation, synaptic vesicle transport, axonal plasticity
- MeSH terms
- Alzheimer Disease, Animals, Humans, Memory Disorders, Nerve Degeneration, Nerve Tissue Proteins, Neural Pathways, Synaptic Transmission, Neuronal Plasticity, Amyloid beta-Peptides, Neurites, Lewy Body Disease, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.